argenx SE (NASDAQ:ARGX) Shares Acquired by Cwm LLC

Cwm LLC lifted its holdings in shares of argenx SE (NASDAQ:ARGXGet Rating) by 42.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 162 shares of the company’s stock after buying an additional 48 shares during the quarter. Cwm LLC’s holdings in argenx were worth $57,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. KB Financial Partners LLC raised its stake in argenx by 112.5% in the 1st quarter. KB Financial Partners LLC now owns 85 shares of the company’s stock valued at $27,000 after purchasing an additional 45 shares during the last quarter. Glassman Wealth Services raised its stake in argenx by 69.4% in the 2nd quarter. Glassman Wealth Services now owns 83 shares of the company’s stock valued at $31,000 after purchasing an additional 34 shares during the last quarter. Captrust Financial Advisors raised its stake in argenx by 116.7% in the 1st quarter. Captrust Financial Advisors now owns 143 shares of the company’s stock valued at $45,000 after purchasing an additional 77 shares during the last quarter. Lindbrook Capital LLC raised its stake in argenx by 32.1% in the 2nd quarter. Lindbrook Capital LLC now owns 144 shares of the company’s stock valued at $55,000 after purchasing an additional 35 shares during the last quarter. Finally, Urban Wealth Management LLC acquired a new position in argenx in the 2nd quarter valued at $64,000. 57.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ARGX. Morgan Stanley raised their target price on argenx from $401.00 to $450.00 and gave the stock an “overweight” rating in a research note on Friday, October 28th. Deutsche Bank Aktiengesellschaft raised their target price on argenx from €400.00 ($434.78) to €425.00 ($461.96) and gave the stock a “buy” rating in a research note on Thursday, September 22nd. Evercore ISI raised argenx to an “outperform” rating in a research note on Friday, October 21st. SVB Leerink raised their target price on argenx from $428.00 to $430.00 and gave the stock an “outperform” rating in a research note on Friday, October 28th. Finally, Stifel Nicolaus raised their target price on argenx from $471.00 to $478.00 and gave the stock a “buy” rating in a research note on Thursday, December 22nd. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $452.83.

argenx Price Performance

Shares of argenx stock opened at $381.98 on Friday. The business has a 50-day moving average of $381.62 and a 200 day moving average of $373.71. argenx SE has a 12 month low of $249.50 and a 12 month high of $407.93. The stock has a market capitalization of $21.13 billion, a price-to-earnings ratio of -22.22 and a beta of 0.80.

argenx (NASDAQ:ARGXGet Rating) last announced its earnings results on Thursday, October 27th. The company reported ($4.26) EPS for the quarter, missing analysts’ consensus estimates of ($3.50) by ($0.76). argenx had a negative net margin of 295.08% and a negative return on equity of 49.53%. The firm had revenue of $146.49 million for the quarter, compared to analysts’ expectations of $115.49 million. Equities research analysts anticipate that argenx SE will post -15.62 earnings per share for the current year.

About argenx

(Get Rating)

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study.

Featured Stories

Institutional Ownership by Quarter for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.